Want to see HK:2607 full AI Analyst Report?
2607 Stock Chart & Stats
HK$11.99
-HK$0.10(-0.83%)
At close: 4:00 PM EDT
HK$11.99
-HK$0.10(-0.83%)
Day’s Range― - ―
52-Week RangeHK$10.96 - HK$12.93
Previous CloseN/A
Volume1.45M
Average Volume (3M)2.90M
Market Cap
HK$65.06B
Enterprise ValueHK$83.31K
Total Cash (Recent Filing)HK$40.98B
Total Debt (Recent Filing)HK$62.41B
Price to Earnings (P/E)10.6
Beta0.69
Next Earnings
Aug 28, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend Yield4.51%
Share Statistics
EPS (TTM)1.55
Shares Outstanding919,072,700
10 Day Avg. Volume2,690,085
30 Day Avg. Volume2,904,360
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.50
Price to Sales (P/S)0.13
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.42
Revenue Forecast (FY)HK$298.63B
Bulls Say, Bears Say
Bulls Say
Integrated Manufacturing And DistributionOwning both manufacturing and a broad distribution channel is a durable structural advantage: it lowers go-to-market friction for new products, increases control over margins and placement, and enables prioritized access to institutional customers, supporting sustained commercial execution over months.
Extensive Distribution Network And Customer ReachA large, established distribution footprint serving hospitals and pharmacies is a structural moat in medical distribution: scale drives purchase frequency, bargaining leverage with suppliers, and customer stickiness, which supports stable volume-driven revenues and resilience to localized demand swings.
Consistent Revenue Growth And Positive Cash GenerationSteady revenue expansion alongside positive free cash flow indicates underlying business durability: consistent top-line growth and cash generation provide resources for reinvestment, service of dividends, and operational stability even with narrow margins, reducing dependence on external financing.
Bears Say
Structurally Thin ProfitabilityVery thin net margins are a persistent structural constraint for the business: low profitability leaves limited buffer against cost inflation or pricing pressure, restricts internal funding for growth or R&D, and makes sustainable improvement dependent on structural changes to mix or efficiency.
Working-capital Intensity And Moderate Cash ConversionMaterial working-capital needs mean earnings do not fully convert to cash, creating variability and limiting free cash available for investment. Moderate FCF conversion (≈63% of net income) raises the risk that earnings growth won't translate directly into stronger cash balances or debt reduction.
Moderate Leverage And Declining ROELeverage at ~0.67 debt/equity combined with falling ROE signals less efficient capital use and higher financial rigidity: moderate indebtedness increases fixed obligations, while declining ROE suggests returns may not justify additional capital deployment without operational improvements.
Shanghai Pharmaceuticals Holding Co News
2607 FAQ
What was Shanghai Pharmaceuticals Holding Co Ltd Class H’s price range in the past 12 months?
Shanghai Pharmaceuticals Holding Co Ltd Class H lowest stock price was HK$10.96 and its highest was HK$12.93 in the past 12 months.
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap is HK$65.06B.
When is Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date is Aug 28, 2026 which is in 17 days.
How were Shanghai Pharmaceuticals Holding Co Ltd Class H’s earnings last quarter?
Shanghai Pharmaceuticals Holding Co Ltd Class H released its earnings results on Apr 29, 2026. The company reported HK$0.442 earnings per share for the quarter, beating the consensus estimate of HK$0.41 by HK$0.031.
Is Shanghai Pharmaceuticals Holding Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Pharmaceuticals Holding Co Ltd Class H’s price is currently Overvalued.
Does Shanghai Pharmaceuticals Holding Co Ltd Class H pay dividends?
Shanghai Pharmaceuticals Holding Co Ltd Class H pays a Semiannually dividend of HK$0.405 which represents an annual dividend yield of 4.51%. See more information on Shanghai Pharmaceuticals Holding Co Ltd Class H dividends here
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate is 0.77.
How many shares outstanding does Shanghai Pharmaceuticals Holding Co Ltd Class H have?
Shanghai Pharmaceuticals Holding Co Ltd Class H has 919,072,700 shares outstanding.
What happened to Shanghai Pharmaceuticals Holding Co Ltd Class H’s price movement after its last earnings report?
Shanghai Pharmaceuticals Holding Co Ltd Class H reported an EPS of HK$0.442 in its last earnings report, beating expectations of HK$0.41. Following the earnings report the stock price went up 0.866%.
Which hedge fund is a major shareholder of Shanghai Pharmaceuticals Holding Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2607
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Pharmaceuticals Holding Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.71%
12-Months-Change
Fundamentals
Return on Equity
4.51%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Shanghai Pharmaceuticals Holding Co Ltd Class H
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, development, production, distribution, and retail of medical and wellness products. The company is strategically divided into Production, Distribution, Retail, and Other segments. Its comprehensive product portfolio includes Western and traditional Chinese medicines, health supplements, and medical devices, addressing a broad spectrum of therapeutic areas such as oncology, cardiovascular health, central nervous system disorders, general infections, immunology, digestive and metabolic conditions, and respiratory ailments, totaling approximately 700 distinct drug varieties. Beyond manufacturing, Shanghai Pharmaceuticals offers extensive pharmaceutical supply chain solutions, encompassing warehousing, logistics, and value-added services for manufacturers, hospitals, distributors, and retail pharmacies. The company also boasts a significant retail footprint, operating a network of approximately 2,000 retail pharmacies across 24 provinces, alongside an active online drug business. Furthermore, it provides various specialized services, including consulting, asset management, clinical trials, medical aid programs, physician and patient education, e-prescription management, and remote/cloud-based hospital services. Established in 1994, Shanghai Pharmaceuticals Holding Co., Ltd. operates as a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―